Contact Us
TEL: +86-0571-88334626
Home > News > Content
Bendamustine Efficacy
Dec 07, 2018

        This product is used for Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, CLL and breast cancer. The dose of blood cancer is 50-60 mg/m2/d, 3 to 5 days or 100-120 mg/m2 every 3 to 4 weeks; solid tumors are 120-150 mg/m2 every 4 weeks, once a day, 30 ~ 60 min intravenous drip. Bendamustine hydrochloride as a single or combination chemotherapy, the response rate of Hodgkin's disease and non-Hodgkin's lymphoma were 61% to 97% and 41% to 48%, respectively. For patients with multiple myeloma, the complete response rate of bendamustine/prednisone was higher (32%), and melphalan/prednisone therapy was more persistent. In the cyclophosphamide, vincristine, and prednisone regimens, bendamustine replaces cyclophosphamide, which has a similar response rate for the development of moderately low-grade non-Hodgkin's lymphoma. In cyclophosphamide, methotrexate, and fluorouracil treatment regimens, bendamustine replaces cyclophosphamide, which extends the remission period in patients with metastatic breast cancer from 6.2 months to 15.2 months.